Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (5y) (2017 - 2025)
Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (5y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn |
| 10 | Nu-Med Plus | 1.82 Mn | 1.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52.24% |
| Sep 30, 2025 | 51.67% |
| Jun 30, 2025 | 58.15% |
| Mar 31, 2025 | 33.51% |
| Dec 31, 2024 | 45.17% |
| Sep 30, 2024 | 34.13% |
| Jun 30, 2024 | 41.31% |
| Mar 31, 2024 | 44.86% |
| Dec 31, 2023 | 30.69% |
| Sep 30, 2023 | 49.85% |
| Jun 30, 2023 | 31.72% |
| Mar 31, 2023 | 27.16% |
| Dec 31, 2022 | 18.49% |
| Sep 30, 2022 | 15.22% |
| Jun 30, 2022 | 11.43% |
| Mar 31, 2022 | 1.95% |
| Dec 31, 2021 | -48.60% |
| Sep 30, 2021 | 29.72% |
| Jun 30, 2021 | -7.07% |
| Mar 31, 2021 | -42.77% |